Department of Surgery, Tohoku University Graduate School of Medicine, Aobaku, Sendai, Japan.
Anticancer Res. 2013 Feb;33(2):685-9.
The purpose of the present study was to examine the possible relation between anorectal carcinoma and infliximab therapy for Crohn's disease.
This study reviewed the medical records of patients with perianal Crohn's disease, who have required surgical intervention at the Tohoku University Hospital since May 2002, when infliximab was approved as a remedy for Crohn's disease in Japan.
Ninety-two patients underwent surgery due to perianal Crohn's disease between May 2002 and December 2011. Four out of 92 patients were diagnosed as having anorectal carcinoma associated with perianal fistula. All four patients had advanced carcinoma, and received infliximab before the diagnosis of cancer was made. Infliximab was administered due to an exacerbated anal lesion in three patients.
Careful inspection and obtaining of a biopsy sample under anesthesia is recommended for patients with Crohn's disease who have long-standing anal fistulas, especially before infliximab administration due to a possible exacerbation of anal symptoms.
本研究旨在探讨肛门直肠癌与英夫利昔单抗治疗克罗恩病之间的可能关系。
本研究回顾性分析了自 2002 年 5 月英夫利昔单抗在日本被批准用于治疗克罗恩病以来,在东北大学医院因肛周克罗恩病而接受手术治疗的患者的病历。
2002 年 5 月至 2011 年 12 月,92 例患者因肛周克罗恩病接受了手术。92 例患者中有 4 例被诊断为与肛周瘘管相关的肛门直肠癌。这 4 例患者均为晚期癌,且在确诊癌症前均接受了英夫利昔单抗治疗。3 例患者因肛门病变加重而使用英夫利昔单抗治疗。
对于患有长期肛周瘘管的克罗恩病患者,尤其是在因肛门症状加重而可能使用英夫利昔单抗治疗之前,建议进行仔细的检查和麻醉下活检,以排除癌症的可能。